This was a phase II/III, randomized, double-blind, placebo-controlled trial COMPARECPM-RMI (CD133, Placebo, MNCs - recent myocardial infarction) conducted in accordance with the Declarationof Helsinki that assessed the safety and efficacy of CD133 and MNCs compared to placebo in patients withRMI. The gene discussed is PROM1; the disease is myocardial infarction.